Qualitative evaluation of a local coronary heart disease treatment pathway: practical implications and theoretical framework
- First Online:
- Cite this article as:
- Kramer, L., Schlößler, K., Träger, S. et al. BMC Fam Pract (2012) 13: 36. doi:10.1186/1471-2296-13-36
- 2.4k Views
Coronary heart disease (CHD) is a common medical problem in general practice. Due to its chronic character, shared care of the patient between general practitioner (GP) and cardiologist (C) is required. In order to improve the cooperation between both medical specialists for patients with CHD, a local treatment pathway was developed. The objective of this study was first to evaluate GPs’ opinions regarding the pathway and its practical implications, and secondly to suggest a theoretical framework of the findings by feeding the identified key factors influencing the pathway implementation into a multi-dimensional model.
The evaluation of the pathway was conducted in a qualitative design on a sample of 12 pathway developers (8 GPs and 4 cardiologists) and 4 pathway users (GPs). Face-to face interviews, which were aligned with previously conducted studies of the department and assumptions of the theory of planned behaviour (TPB), were performed following a semi-structured interview guideline. These were audio-taped, transcribed verbatim, coded, and analyzed according to the standards of qualitative content analysis.
We identified 10 frequently mentioned key factors having an impact on the implementation success of the CHD treatment pathway. We thereby differentiated between pathway related (pathway content, effort, individual flexibility, ownership), behaviour related (previous behaviour, support), interaction related (patient, shared care/colleagues), and system related factors (context, health care system). The overall evaluation of the CHD pathway was positive, but did not automatically lead to a change of clinical behaviour as some GPs felt to have already acted as the pathway recommends.
By providing an account of our experience creating and implementing an intersectoral care pathway for CHD, this study contributes to our knowledge of factors that may influence physicians’ decisions regarding the use of a local treatment pathway. An improved adaptation of the pathway in daily practice might be best achieved by a combined implementation strategy addressing internal and external factors. A simple, direct adaptation regards the design of the pathway material (e.g. layout, PC version), or the embedding of the pathway in another programme, like a Disease Management Programme (DMP). In addition to these practical implications, we propose a theoretical framework to understand the key factors’ influence on the pathway implementation, with the identified factors along the microlevel (pathway related factors), the mesolevel (interaction related factors), and system- related factors along the macrolevel.
KeywordsPrimary health careCoronary artery diseaseClinical pathwaysQualitative research
Despite the declining mortality of patients in recent years with coronary heart disease (CHD) in Western countries [1, 2], CHD remains the leading cause of morbidity and mortality in adults worldwide . In the United States, about 7.0 % (women) to 9.1 % (men) of the general population are affected by CHD . Similar prevalence rates (women: 6.5 %, men: 9.2 %) have been found in Germany . Most patients with CHD need lifelong, continuous, complex medical care, which is extremely costly to the healthcare system .
In this context, an important role is attached to the shared care of patients with CHD by the general practitioner (GP) and the cardiologist. Better coordination and communication between GP and medical specialist promises optimized medical treatment along with increased cost-effectiveness in primary care [7–9]. Improving the cooperation between different health care professionals and providing optimal evidence-based medical care for patients are the main objectives of clinical guidelines . For CHD, it was demonstrated that non-adherence to medical recommendations is associated with a broad range of adverse outcomes in patients . Despite the high scientific quality of most guidelines and their wide promulgation, their actual impact on clinical practice and quality of care is limited [12–15]. Numerous international studies have shown that effective and lasting behaviour change of health care professionals is difficult to achieve and is influenced by multiple factors [16–18]. Although guidelines may be seen as necessary to provide valid recommendations, they are insufficient in ensuring evidence-based decision-making . In this context, the use of clinical pathways as one approach to facilitate the adaption of research findings in daily practice is important. Clinical pathways are multidisciplinary, locally translatable, and involve a stepwise procedure, determined timeframes, and standardized care for a specific clinical problem . Even though the implementation of clinical pathways faces similar problems as the implementation of guidelines [21, 22], some authors [19, 23, 24] expect treatment pathways to raise implementation chances by adapting the guideline recommendations to local conditions and thereby referring more to physicians’ work reality. However, the effect of local treatment pathways is controversial, as Salegy and colleagues  rarely found an implementation benefit by the local adaption. Additionally, the local adaption was associated with higher costs compared to national guidelines. Nevertheless, the development and use of a local pathway might be appropriate in situations where an additional advantage is expected by its use. This might be of importance if system related factors require local adjustments .
To date, most experience with treatment pathways is gained in countries with a Beveridge type of health care system, characterized by a strong governmental influence. In countries like Germany, where a Bismarck type of health care system is established , the implementation of shared care pathways poses a special challenge as they are less regulated by institutional standards. Patients have universal medical access with only a very limited gate-keeping role of the GP. Due to the system structure, competition between medical professionals in the ambulatory sector (primary and secondary care) hinders cooperation. Thus, despite a greater need for coordination, the establishment of shared care pathways is paradoxically much more difficult to achieve in Bismarck types of health care systems. By developing and implementing a shared care pathway for patients with CHD in a Bismarck type system, we intended to close this gap and contribute a new aspect to existing research primarily made in the Beveridge type of health care systems.
Within this context of developing and evaluating a local CHD pathway we pursued two objectives in this study. On the one hand we aimed to evaluate GPs’ opinion regarding the pathway and give practical implications for clinical practice that derived from this evaluation. On the other hand we strived to abstract our findings by putting the identified key factors influencing the pathway implementation into a multi-dimensional model.
Development and description of the CHD pathway
In 2008, GPs and cardiologists from the Marburg region, Germany, were invited by the Department of General Practice at the University of Marburg to jointly develop a local treatment pathway for patients with CHD. By involving end-users in the pathway development and thus considering their experience and expertise of daily practice, we realized a bottom-up approach . It was assumed that a cooperatively developed local consensus with the collaboration of GPs and cardiologists would improve GPs’ and cardiologists’ acceptance and adherence to the corresponding guideline recommendations for the handling of CHD patients in primary care .
The development of the pathway was based on current regional  and national care guidelines . Within small working groups moderated by members of the department, plans for monitoring visits, relevant drugs, and documentation forms were developed and brought to a consensus with all participants. To support the implementation of the pathway in daily practice, we provided the physicians with both a laminated pocket version of the pathway guidelines covering drugs and monitoring visits, and patient treatment logs to list medication and monitoring visits for every patient. An overview of the pocket version of the pathway is given in Additional file 1.
In brief, the larger project aimed to improve the shared care of patients with CHD by GPs and cardiologists. The quantitative study investigated physicians’ adherence to pathway recommendations regarding the prescription of drugs and the referrals to the cardiologist, and its impact on patient variables such as satisfaction with the treatment and health-related quality of life. The analysis of the quantitative results and its relation to the qualitative data (triangulation) is in progress and will be reported soon. To gain further insight into GPs’ opinion regarding the pathway and the factors influencing GPs’ decision to (not) implement the CHD pathway, we conducted this qualitative study in the middle of the feasibility study so that physicians’ experience with the pathway could be ascertained. Face-to-face interviews were undertaken during February and March 2010 in the physicians’ practices by one of the authors (LK) who was not involved in the development of the pathway.
In our study we aimed not only to report the results of the interviews and their practical implications, but to identify the latent pattern of the data. According to Sandelowski and Barroso, this more explanatory than exploratory interpretation of the qualitative data can be categorized as thematic/conceptual as we provide a theoretical framework of our findings . The results gained in our study, like those of the quantitative study, may inform the planning and conducting of an subsequent randomised controlled trial (RCT) evaluating the efficacy of the CHD pathway .
GPs and patients were informed in detail about the study and all gave their written consent to the study participation. Ethical approval for the study was obtained from the Ethics Committee of the Faculty of Medicine at the Phillips University of Marburg, Germany.
Participants and recruitment procedures
Within the context of the feasibility study, we asked all 12 pathway developers (8 GPs and 4 cardiologists) and the 6 pathway users, familiar with the pathway recommendations, to participate in our qualitative evaluation study. Thus, by selecting respondents that were most likely to yield useful information about the key factors influencing the pathway implementation, we used a purposeful sampling strategy  and considered our sample size as appropriate to achieve saturation . As the GPs of the control group did not know the pathway, we did not include them in the study. All physicians from the intervention groups were located in the Marburg region, Germany, and were recruited from the regional physician network of the Department of General Practice at the Phillips University of Marburg, Germany. The GPs from the control group were located in a neighbouring town.
The interviews were based on a semi-structured interview guideline covering the attitude towards the developed pathway and medical innovations such as treatment pathways and guidelines in general, key factors that influenced the implementation of the CHD pathway in a negative or positive way, and suggestions of improvement and behaviour changes in consequence of the pathway. The interview guideline was developed jointly by two of the authors (LK, NDB) and was aligned with previously conducted studies from our department on changes of professional behaviour [34, 35] and the components of the theory of planned behaviour (TPB) . Interview participants were assured that their responses would remain confidential and anonymous.
Interviews were audio-taped and transcribed verbatim. The accuracy of transcripts was checked prior to being transferred to the computer software program Maxqda 2007 , which assisted data handling. Based on the interview guideline, a thematic coding frame for the analysis of the interviews’ content was developed by the authors (LK and KS). The first three interviews were coded and then the evaluation of the coding frame was discussed. Within the analysis process no further categories emerged, so we considered theme saturation as achieved. Transcripts were coded separately by LK and KS and then checked for consistency. The data analysis and interpretation followed the standards of qualitative content analysis . The translation of the quotes from German to English was conducted by a qualified translator.
Demographics of the study sample: GPs and cardiologists (n = 16)
Demographics and professional characteristics
41 to 50
51 to 60
Established since (years)
11 to 20
Characteristic of the practice
5000 to 20.000
20.000 to 100.000
Agreement with the treatment pathway
Key factors influencing the (non-)implementation of the treatment pathway
Classification of the key factors influencing the pathway implementation
· Pathway availability
· Assessment of guidelines
· Application area
· “Cookbook medicine” vs. individuality
· Improvements of implementation strategies
· Behaviour change
· PC Version
· Disease Management Program (DMP)
· Health care system
As this study was undertaken to gain additional insight into the relevant key determinants for implementation, we focused a cross-case analysis on the identification of general factors and were less interested in interindividual differences.
Pathway related factors
The first major theme in this category dealt with the pathway content. Many of the participating GPs and cardiologists (C) considered the CHD pathway as a useful and high quality treatment aid.
“The treatment pathway is good to create a standard framework of how to interact with certain patients, so that it is clear for everybody. I think it’s a reasonable thing.” [C1]
“I think it’s actually useful to have such an aid. It improves your awareness for things you should keep an eye on. To my delight, the number of beta blockers was reduced and more certainty was provided regarding the sequence of cardiological consultations.” [GP2]
The effort created by the implementation of the pathway in daily practice was perceived as controversial by the interviewees. While the case record form (CRF) documentation for the evaluative study was assessed as time consuming, the application of the pathway in practice was rated as time saving, or no difference was recognized.
“It was time consuming to somehow record [the patients’ medication history]. The second time around it was no problem because in most cases nothing had changed. You could copy [the information] or just refer to the first record. Integrating [the information] is not a problem now, unlike the first time.” [GP6]
“I would say that [the pathway] certainly saves time, [especially] for colleagues who haven’t followed [the pathway’s recommendations] or have yet to really put the drug therapy into practice.” [GP1]
A relevant issue for the participating physicians was the balance between ‘cookbook medicine’ by a high adherence to the pathway’s recommendations and an individual treatment of the patient. On the one hand, participants appreciated the standardised treatment guideline, on the other hand, they emphasized the consideration of intuition and experience in the consultation.
“It is indeed like cookbook medicine, but on the other hand, it makes one feel safer. And I think that every one of us has a certain plan of how to proceed for every clinical situation. And those [plans] could be standardized. Then you can say ‘Ok, we consistently proceed according to this model, to this scheme.’ I think this is good.” [GP7]
“As a doctor, I want to maintain individual treatment. I am the one who decides based on my twenty years of experience in cardiology. I do not want the pathway to tell me what I have to do. Guidelines are only guide rails within which you can act.” [C1]
The participation in the development of the pathway was an important factor for the physician’s evaluation of the CHD treatment tool. Overall, the participation resulted in a positive evaluation, even though concessions had to be made.
“Our behaviour informed the pathway, like always. I support [the pathway]; we worked on [its development] for a long time. It was extensively discussed before everybody could agree on its final version. So I perceived [the pathway development] as positive.” [C2]
“You are not bound to a guideline that was imposed from above, but in whose development we took part, and which we could influence. This is what makes it good. If you contribute to such a thing, then it is something you support. My ideas are included and the way I think you should act. And, therefore, I am totally in support of it.” [GP1]
“We could not enforce [the frequency of cholesterol measurement]. When you make decisions as a group you have to swallow some bitter pills.” [C3]
The appraisal of their own behaviour in the past was an important factor for physicians’ willingness to implement the pathway. Many interviewees felt that they had treated their patients with CHD according to the pathway recommendations during previous visits.
“[Our behaviour] has not changed a lot. We have not invented something new, but have, in principle, implemented the guidelines.” [GP5]
“Actually, I acted like I always did: the patients came in regular intervals, we talked about the disease, we talked about incidents, we talked about the cardiological report, and we checked the laboratory parameters and drugs.” [GP6]
The participating GPs expressed a desire to integrate the pathway recommendations into practice software. A PC integration was perceived as facilitating the embedding of the pathway in daily practice, e.g., the schedule for monitoring visits. Concerning the need for regular refresher meetings, the physicians had heterogeneous opinions: On the one hand the knowledge update was appreciated; on the other hand regular meetings were seen as too time-consuming or simply unnecessary.
“Of course we would keep recommendations in mind with regular training sessions, but we already have so many continuing medical education (CME) events. So it is not necessary.” [GP3]
“I think it’s reasonable to have regular trainings so that it becomes second nature [to us doctors]. I think this is very important.” [GP1]
Patients’ acceptance of and compliance with the pathway recommendations were rated high by the interviewees if the pathway recommendations were thoroughly explained. Furthermore, the participating physicians reported that knowledge of the patient’s background, e.g., medical history and psychosocial conditions, may influence the application of the pathway. This can be reflected in either patient related assumptions or routine actions in the consultation.
“And for the patient it [the pathway] is actually better. He stays more compliant because he knows it is not back and forth but a routine program that he gets every time. This makes the patients feel safer.” [GP8]
“Of course we act according to the disorders and the risk profile, but we know the patients from their domestic conditions and whether they comply or not. And in these cases I would vary [the treatment].” [GP9]
“Being aware gets lost sometimes, especially when you have had patients for years or take over a practice and there are listed diagnoses and drugs, so you do not always question everything, you just overlook things.” [GP2]
The cooperation between GPs and cardiologists was appreciated by both sides. Apart from smaller disagreements concerning coordination responsibility for the CHD patients, or adherence to the pathway advice, the collaboration was described as positive.
“We actually understood it as the treatment pathway helps us to do our job, and that one part of that - what we have done before - is connected to the primary care treatment. If we collaborate with competent GPs, we already tend to tell our patients that they have a competent GP to whom they should primarily turn to, e.g., when deterioration happens.” [C3]
“No problem now, [the cooperation] has improved considerably. The cardiologists do not make it their responsibility to schedule monitoring visits, instead leaving it more to the GP`s discretion. [Cardiologists] complained that many [patients] come to unnecessary monitoring visits, but now I think it is working better.” [GP10]
By integrating the pathway into a larger geographic, such as nationwide or organizational contexts, e.g., a medical association, the interviewed physicians expected an increased implementation success of the tool. The overlap between the pathway and the German CHD Disease Management Program (DMP) as systematic treatment program for chronically ill people [6, 39] was seen as an impeding factor for the pathway implementation in cases of differing recommendations.
“But I think that one can and should implement [the pathway] at the health care system level. One could, for example do [the pathway implementation] with our medical association and raise it to another level.” [C2]
“Because we are bound by contract to the DMP, we are obligated to act correspondingly. Even if we found the treatment pathway more reasonable, we are forced to implement the DMP. Sanctions are partially imposed if you do not participate in the DMP.” [GP7]
Health care system
Participants perceived the actual demands of the German health care system as influencing the implementation of the CHD pathway. Due to competing tasks in daily practice, the pathway would be at risk of being forgotten. The GPs named their small gate-keeping influence in the German health care system as influencing factors for appointments with medical specialists as patients have free access to specialised care.
“We have so many fires burning at the moment, so many contracts, special regulations and treatment plans, DMP situations and such, that we partly lose the big picture. That makes it difficult for us.” [GP7]
“Thus, there is so much to work on at the moment. I think that is the main reason for not optimally meeting the requirements of every patient.” [GP9]
“I actually see another essential problem in, such is it here, we have free choice of care and many people go to secondary care on their own decision.” [GP7]
Our study complements the understanding of potential facilitators and barriers to be considered in planning the implementation of innovative tools like the CHD pathway and is in line with the findings of other international studies [10, 16, 17, 40].
Concerning the treatment pathway itself, we first assessed the pathway content, the participation in the pathway development/ownership, the individual flexibility, and the related effort as relevant aspects for the implementation. The overall evaluation of the pathway recommendations was positive and required no additional effort by some of the GPs. Referring to the pathway development, which was appreciated by the physicians, a study by Grimshaw and colleagues showed that the participation in developing a guideline could enhance the compliance in physicians by about 32 %, whereas it was 22 % for non-developers . Additionally, the active involvement of end-users in the local adaptation of clinical guidelines was found to lead to lead to significant changes in practice through a sense of ownership [19, 41]. As seen in other studies, the interviewed physicians perceived the ambivalence between the facilitation by standardized guidance and the restriction of their own medical autonomy as relevant [42–44].
In addition to the aspects related to the pathway, we identified further relevant factors. On a behaviour-related level we identified previous behaviour and support as important factors for pathway implementation. Located on an interactional level and consistent to other research, the patients’ acceptance of the pathway and the physicians’ cooperation with their colleagues were assessed as important components for the implementation of the pathway . Patients’ acceptance of the recommendations of the pathway was rated high by the physicians. In accordance with a study by Summerskill and Pope, our findings suggest that a physician’s knowledge of a patient’s background is an influencing factor for the successful implementation of medical innovations . As a result, this could lead to assumptions, which then exclude or include specific treatments for certain patients, for example those with a certain risk profile. Contrarily, physicians’ knowledge of a patient’s background may also result in routine actions in the consultation, which may lead to overlooking other indications.
Finally, on a system level, an effective use of the CHD pathway depends on both the health care system and the context in which the medical implementation occurs.
Considering the impact of contextual factors for the successful implementation of medical innovations is an aspect also mentioned by other authors [40, 46]. We aimed to raise the pathway’s implementation success by realizing a bottom-up approach and local attuning in the development and implementation of the CHD pathway; this can be seen in other studies where the application of a bottom-up strategy led to improvements in outcomes of care [47, 48]. In contrast to these findings, our results suggest that physicians also attach importance to enabling features that can be centrally provided, such as embedding the pathway in a DMP, or providing regular trainings.
Even though the overall evaluation of the pathway recommendations was positive, this appreciation did not automatically lead to a behaviour change as some physicians reported to have already been treating their patients as the pathway recommends. According to the theory of planned behaviour (TPB) , attitude is an important factor for behaviour change, but our study reveals that on its own it is an insufficient precondition for a lasting implementation of the pathway. Thus, to enhance the adaptation of the pathway in daily practice, an appropriate implementation strategy is required. As the effectiveness of single measures depends on the context, the professional group or the disease , an individually designed strategy that includes different components is thought to be most promising . A first step to raising the awareness of the physicians might be to modify the layout of the laminated pocket version as a pathway-related factor. Another approach facing interactional and behavioural factors is to establish regular quality circles where the appropriate use of the pathway is discussed and supervised. Some of the interviewed physicians felt that their individual treatment flexibility was limited by the pathway as it proposes a structured treatment plan. Thus, to prevent a complete rejection of the pathway, it might make sense to broaden coarsen the recommendations and give benchmarks instead of detailed instructions. Being aware that GPs’ perception of conformity does not necessarily correspond to real facts, further research must be undertaken to investigate a supposed perception-reality gap.
As mentioned by the physicians, the implementation of the pathway would be eased by its integration into PC software and thus simplify and standardize recall possibilities. Another factor influencing the pathway implementation are competing recommendations of the pathway and the German DMP, as the DMP includes mostly similar, but sometimes aberrant recommendations and different timetables. A possible practical implication would be to embed the pathway recommendations directly in a DMP, or taking the DMP recommendations into account during the process of pathway development.
We thereby considered two dimensions: temporal sequence and content. We assumed that the key factors influencing the implementation of the CHD treatment pathway can be classified according to their impact in the pre-intervention, e.g., previous behaviour, the present-intervention, e.g., pathway material, or the post-intervention period, e.g., support. Referring to the Ecological System Theory by Bronfenbrenner  and based on a similar model developed in our department , we differentiated between several levels of the health care sector, namely the micro-, meso- and macrolevel. Additionally, our model shows similarities with the conceptual framework proposed by Sorensen and colleagues, which addresses the social context (including individual, interpersonal, organizational and neighbourhood/community factors) as essential for behaviour change . Thus, the pathway-related factors were arranged along the microlevel, the interaction-related factors along the mesolevel, and the system-related factors along the macrolevel. Due to their primary time-related impact, the behaviour-related factors were excluded from this content-related classification within the model.
We do not claim completeness of the aforementioned factors or categories, nor do we provide an algorithm of how the presence or absence of the reported key factors attributes to the relative implementation success of the pathway. Our interest was to propose a theoretical framework that might serve as background for further implementation research.
As a result of the qualitative study design and the small study sample, the representativeness of the data may be limited. In addition, the selection bias caused by the fact that only motivated and interested physicians participated in the study may influence the representativeness of the results. A possible bias by social desirability in the face-to-face interviews cannot be excluded. Nevertheless, due to the meaningful results and conclusions gained in a Bismarck type of health care system, we presume the chosen method to be appropriate for our research question [53–55], which is aimed more at involved components than defined outcome measures .
Another limitation concerns the proposed multi-dimensional model. The distinction between the time- and level-related categories should not be seen as static. The model is a draft with flexible confines between the singular categories and has to be proven in further research. For example, due to its actual impact, we related the pathway development to a present point in time; putting this factor in the past would have been another possibility. We did not investigate possible differences in the response patterns of pathway developers and pure users, or GPs and cardiologists, while the research question focused on the identification of general factors influencing the pathway implementation rather than on interindividual differences.
As our research dealt primarily with external implementation factors and final outcomes, the role of underlying psychological and interactional processes will need to be investigated in future studies. In addition to cognitive or affective processes like self-efficacy expectancy , general implementation processes and implementation fidelity [58–60] should also be evaluated.
Our study demonstrated that the implementation of medical innovations like the reported CHD treatment pathway is influenced by multiple components. Besides reporting the factors influencing the pathway implementation and giving practical implications how to improve pathway implementation, we proposed a theoretical framework by arranging the findings in a multidimensional model and thereby add innovative aspects to the already existing implementation research. Fields scarcely investigated collectively in Bismarck type of health care systems, like bottom-up developed local pathways and the integration of primary and secondary care, are considered.
We thank all participating practices and Muazzez Ilhan and Marion Herz-Schuchhardt for their study assistance. We also would like to thank Juliette Rautenberg for her help in improving the precision and fluency of the manuscript. The study was funded by the German Ministry of Education and Research (BMBF) Grant Nr. 01GK0701.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.